Vergoeding 2020-2024 voor ATC-subgroep N07XX : Overige middelen werkzaam op het zenuwstelsel
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| N07XX02 Riluzol (Emylif ®) | 992.240 | 979.820 | 999.330 | 1.248.800 | 1.464.200 |
| N07XX04 Hydroxyboterzuur (Xyrem ®) | 4.045.800 | 3.506.000 | 3.188.000 | 3.251.300 | 3.260.000 |
| N07XX05 Amifampridine (Firdapse ®) | 1.839.700 | 1.827.500 | 2.072.000 | 2.291.500 | 2.365.400 |
| N07XX06 Tetrabenazine (Tetmodis ®) | 221.800 | 256.320 | 255.530 | 277.860 | 282.700 |
| N07XX07 Fampridine (Fampyra ®) | 6.581.800 | 7.229.500 | 8.402.600 | 9.350.200 | 9.291.700 |
| N07XX08 Tafamidis (Vyndaqel ®) | 3.879.500 | 3.545.500 | 26.845.200 | 41.813.800 | 58.269.700 |
| N07XX11 Pitolisant (Wakix ®) | 1.081.800 | 1.170.100 | 1.303.000 | 1.403.600 | 1.353.400 |
| Totaal | 18.642.640 | 18.514.740 | 43.065.660 | 59.637.060 | 76.287.100 |